Total revenues for Q3FY17 were down 6.9% YoY while EBITDA margins declined from 39.1% in Q3FY16 to 20.2% in current quarter mainly attributable to US business (declined 44.4% YoY) which dipped on account of increased competition in limited competition drug and...